OncoCyte Corporation (NYSE MKT:OCX) Q1 2020 Earnings Conference Call - Final Transcript

May 12, 2020 • 04:30 pm ET


OncoCyte Corporation (NYSE MKT:OCX) Q1 2020 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Greetings, and welcome to the Oncocyte Corporation's First Quarter 2020 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host, Bob Yedid of LifeSci Advisors. Please go ahead, sir.

Robert Yedid

Thank you, Jerry, and thank you, everyone, for joining us for today's conference call to discuss Oncocyte's first quarter 2020 financial results and recent operating highlights. If you have not seen today's financial press release, please visit Oncocyte's website at www.oncocyte.com.

Before turning the call over to Ronnie Andrews, Oncocyte's President and Chief Executive Officer, I would like to remind you that during this conference call, the Company will make projections and forward-looking statements regarding future events. Any statements that are not historical facts including, but not limited to, statements that contain words such as will, believes, plans, anticipates, expects, estimates and similar expressions are forward-looking statements. We encourage you to review the Company's SEC filings, without limitation, the Company's forms 10-K and 10-Qs, which identify the specific risk factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, risks inherent in the development or the commercialization of potential diagnostic test, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Oncocyte's third-party supply blood sample analytic system to provide consistent and precise analytic result on a commercial scale, the need to obtain both third-party reimbursement for patients use of any diagnostic test the Company commercializes, our need and ability to obtain future capital, maintenance of intellectual property rights and the potential impact of COVID-19 on Oncocyte's financial and operational results. Therefore, actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements. Oncocyte expressly disclaims any intent or obligation to update these forward-looking statements as otherwise may be required under applicable law.

With that, it's now my pleasure to turn the call over to Ronnie Andrews, CEO. Ronnie?

Ronald A. Andrews

Hey, thanks, Bob, and welcome, everyone, to our conference call to discuss our first quarter 2020 financial results and operating highlights. Joining me today, mostly virtually, are Mitch Levine, our Chief Financial Officer; Al Parker, our Chief Operating Officer; Dr. Lyndal Hesterberg, our Chief Science Officer; Dr. Doug Ross, our Chief Medical Officer; and Padma Sundar, our Senior Vice President, Commercial. All of these folks will be available during the question-and-answer session.

Thanks to the unparalleled commitment and sacrifice of our amazing team, I'm very encouraged to start today's call being able to say that we have continued our significant momentum through the first quarter of 2020, and as you'll hear on the call today, have made considerable progress in pivoting the Company's strategy and are now beginning to realize our mission, even as we face the current macro environmental headwinds. I think most exciting is our big news for DetermaRx, the first and only predictive test for the identification of patients with Stage I